1. Home
  2. ANAB vs PRO Comparison

ANAB vs PRO Comparison

Compare ANAB & PRO Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

  • Machine Learning Prediction
  • ML Decision
  • ANAB
  • PRO
  • Stock Information
  • Founded
  • ANAB 2005
  • PRO 1985
  • Country
  • ANAB United States
  • PRO United States
  • Employees
  • ANAB N/A
  • PRO N/A
  • Industry
  • ANAB Biotechnology: Pharmaceutical Preparations
  • PRO EDP Services
  • Sector
  • ANAB Health Care
  • PRO Technology
  • Exchange
  • ANAB Nasdaq
  • PRO Nasdaq
  • Market Cap
  • ANAB 759.5M
  • PRO 898.3M
  • IPO Year
  • ANAB 2017
  • PRO 2007
  • Fundamental
  • Price
  • ANAB $22.23
  • PRO $17.58
  • Analyst Decision
  • ANAB Buy
  • PRO Strong Buy
  • Analyst Count
  • ANAB 10
  • PRO 10
  • Target Price
  • ANAB $42.25
  • PRO $29.40
  • AVG Volume (30 Days)
  • ANAB 559.5K
  • PRO 575.6K
  • Earning Date
  • ANAB 05-05-2025
  • PRO 07-29-2025
  • Dividend Yield
  • ANAB N/A
  • PRO N/A
  • EPS Growth
  • ANAB N/A
  • PRO N/A
  • EPS
  • ANAB N/A
  • PRO N/A
  • Revenue
  • ANAB $111,872,000.00
  • PRO $336,006,000.00
  • Revenue This Year
  • ANAB N/A
  • PRO $10.25
  • Revenue Next Year
  • ANAB $9.72
  • PRO $10.47
  • P/E Ratio
  • ANAB N/A
  • PRO N/A
  • Revenue Growth
  • ANAB 387.20
  • PRO 7.97
  • 52 Week Low
  • ANAB $12.21
  • PRO $14.81
  • 52 Week High
  • ANAB $41.31
  • PRO $30.67
  • Technical
  • Relative Strength Index (RSI)
  • ANAB 62.32
  • PRO 48.93
  • Support Level
  • ANAB $20.50
  • PRO $16.69
  • Resistance Level
  • ANAB $22.84
  • PRO $18.33
  • Average True Range (ATR)
  • ANAB 1.28
  • PRO 0.56
  • MACD
  • ANAB 0.12
  • PRO 0.04
  • Stochastic Oscillator
  • ANAB 83.24
  • PRO 38.70

About ANAB AnaptysBio Inc.

AnaptysBio Inc is a clinical-stage biotechnology company. The company is focused on developing antibody product candidates for unmet medical needs in inflammation and immuno-oncology. The company is developing immune cell modulating antibodies, including two wholly owned checkpoint agonists in clinical-stage development, for autoimmune and inflammatory diseases; rosnilimab, our PD-1 agonist in a Phase 2b trial for the treatment of moderate-to-severe rheumatoid arthritis (RA) and a Phase 2 trial for the treatment of moderate-to-severe ulcerative colitis (UC); and ANB032, our BTLA agonist, in a Phase 2b trial for the treatment of moderate-to-severe atopic dermatitis (AD).

About PRO PROS Holdings Inc.

Pros Holdings Inc. is a provider of cloud-based revenue and profit realization software solutions to business-to-business and business-to-consumer companies. Its solutions assist customers in growing revenue, modernizing business processes, and supporting profitability by leveraging prescriptive analytics and data science-based decision-making technology. The company's solutions enable buyers to move fluidly across its customers' direct sales, partner, online, mobile, and emerging channels with personalized experiences. The firm generates revenue in the United States, Europe, Africa, Asia-Pacific, and Middle East regions.

Share on Social Networks: